| abstract |
This document provides methods and materials for predicting whether a prostate cancer patient is likely to respond to an androgen deprivation therapy for a prolonged period of time. For example, methods and materials for predicting whether or not a prostate cancer patient is likely to respond to an androgen deprivation therapy for a prolonged period of time based at least in part on the presence of an elevated level of 17-β-estradiol, an elevated level of estrone, an elevated level of a neuropilin-2 polypeptide, a reduced level of a zinc alpha-2 macroglobulin polypeptide, or a combination thereof are provided. This document also provides methods and materials for treating prostate cancer patients. |